https://www.selleckchem.com/products/AZD0530.html BACKGROUND/AIM Previous reports have demonstrated that non-steroidal anti-inflammatory drugs (NSAIDs) are a risk factor for cisplatin-induced nephrotoxicity (CIN). Here, the results of these previous studies were comprehensively assessed via a meta-analysis. MATERIALS AND METHODS After a database search to select eligible studies, a meta-analysis was performed using a forest plot, followed by an assessment of the heterogeneity and publication bias and a subgroup analysis. RESULTS Seven studies were extracted as candidates. All were retrospective studies and evaluated the effect of NSAIDs on CIN as a secondary endpoint. According to the meta-analysis, total odds ratio was 1.88 (95% confidence interval=1.44-2.45). Further, high heterogeneity and publication bias were not observed. A subgroup analysis of the chemotherapy evaluation period revealed that CIN tended to be enhanced in the first course group (evaluation in only 1 course) and was significantly enhanced in the total course group (evaluation in 1 or more courses) by NSAIDs co-administration. CONCLUSION NSAIDs co-administration could be a risk factor for CIN. BACKGROUND/AIM The present study examined the impact of systemic inflammatory markers including C-reactive protein (CRP)/Albumin (Alb) and neutrophil lymphocyte ratio (NLR)/Alb on the prognosis of patients treated with first line molecular targeted therapy for advanced RCC. PATIENTS AND METHODS A total of 131 patients with advanced RCC treated with molecular targeted therapy as first line treatment from May 2008 to April 2019 were retrospectively analyzed. RESULTS High CRP, high NLR, low Alb and high CRP/Alb showed significantly worse progression-free survival (PFS) and overall survival (OS) than low CRP, low NLR, high Alb, low CRP/Alb and low NLR/Alb, respectively. In multivariate analyses, prior nephrectomy (p=0.0321) and NLR/Alb ratio (p=0.0327) were independent prognostic factors for PFS. Furthermore, p